Knight Therapeutics
A cash-rich pan-Latin-American and Canadian specialty-pharma platform now growing revenue and EBITDA quickly.
The business
Knight Therapeutics acquires, in-licenses and distributes branded pharmaceutical products across Canada and Latin America, focused on specialty and branded generics.
It has historically carried a large cash balance as optionality for deals, and is now converting that into a growing operating business.
The moat
A built-out pan-Latin-American commercial and regulatory distribution platform is hard to replicate and gives partners a single route to the region.
A strong, largely net-cash balance sheet provides deal-making optionality.
Related on CoinCompass: Compound interest calculator · Guides. For the underlying numbers, see Knight Therapeutics Q1 2026 results (GlobeNewswire).
Financial snapshot
Most recent reported period : Q1 FY2026 (ended March 31, 2026). Figures reflect the review date — confirm current numbers before acting.
| Revenue (Q1) | >C$148M (+68% YoY) |
| Adjusted EBITDA (Q1) | C$28M (+130% YoY) |
| Cash & securities | ≈C$127M (net cash ≈C$69M) |
| FY2026 revenue guidance | C$510–525M (raised) |
| FY2026 adj. EBITDA target | ≈15% of revenue |
Free cash flow yield & sustainable growth
Free cash flow yield : ≈4% (est.)adj. EBITDA ≈15% of ~C$515M revenue vs ~C$0.96B market cap
For a growing specialty-pharma platform, watch the trajectory of EBITDA-to-cash conversion alongside the net-cash balance sheet — Knight is early in turning strong EBITDA growth into consistent free cash flow.
The roughly C$127M of cash and securities (net cash ≈C$69M) is both a margin of safety and dry powder for the tuck-in acquisitions that drive the model.
Sustainable growth: fueled by product launches and acquisitions across Latin America; trailing revenue is up ~39%, with FY2026 guidance raised — durable if the deal pipeline and launches continue.
Valuation & what to watch
Knight has often traded near its book value, treated by the market as a 'cash-plus-optionality' story rather than an operating compounder.
That framing is being tested as revenue (+68% in Q1) and EBITDA (+130%) scale — the question is whether the market re-rates it as a genuine growth platform.
Dividend
Not an income stock — Knight retains capital for acquisitions and buybacks rather than paying a meaningful dividend.
Risks & the bear case
- Latin American currency and macro volatility.
- Product and supplier concentration; launch timing.
- Capital-allocation track record is scrutinized given the historical cash pile.
- Integration and regulatory risk across multiple jurisdictions.
Recent developments
Q1 FY2026 revenue topped C$148M (+68%) with adjusted EBITDA of C$28M (+130%); Knight raised FY2026 revenue guidance to C$510–525M while holding ≈C$127M in cash and securities.
Verdict
A cash-backed specialty-pharma platform finally showing real operating growth. The bull case is a re-rating from 'cash story' to 'growth platform' as EBITDA scales; the bear case is Latin American volatility and lumpy deal-driven results. Conviction: growth-plus-optionality idea for investors comfortable with EM exposure.
Sources
CoinCompass is a publisher, not a registered investment adviser. This is factual information and opinion for a general audience — not a recommendation to buy or sell any security, and not individualized advice. Figures are the most recent reported at the review date and will change. The author, John Wilson, has disclosed long-term holdings in Canadian equities (including Boyd Group, Constellation Software and MTY Food Group) and may hold positions in securities discussed. Do your own research or consult a licensed professional. See our disclosures. John Wilson → · disclosures →